TriSalus Life Sciences (NASDAQ:TLSI) Shares Down 4.6% - Should You Sell?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report)'s stock price fell 4.6% on Tuesday . The company traded as low as $4.18 and last traded at $4.34. 72,578 shares changed hands during trading, an increase of 100% from the average session volume of 36,327 shares. The stock had previously closed at $4.55.

TriSalus Life Sciences Trading Down 1.2%

The firm has a market cap of $158.17 million, a price-to-earnings ratio of -3.73 and a beta of 0.50. The business's 50-day simple moving average is $5.07 and its two-hundred day simple moving average is $5.27.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the previous year, the company earned ($0.60) earnings per share. On average, analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Insider Activity at TriSalus Life Sciences

In other news, insider Richard Marshak sold 6,597 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the sale, the insider owned 69,101 shares of the company's stock, valued at $357,943.18. This trade represents a 8.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 16,125 shares of company stock worth $83,528. Company insiders own 27.50% of the company's stock.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently modified their holdings of TLSI. Charles Schwab Investment Management Inc. acquired a new stake in shares of TriSalus Life Sciences during the 1st quarter worth approximately $55,000. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences during the 4th quarter worth $67,000. Connective Capital Management LLC purchased a new position in TriSalus Life Sciences during the 4th quarter worth $140,000. Northern Trust Corp boosted its holdings in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in TriSalus Life Sciences during the 1st quarter worth $187,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.